Auris Medical Holding AG (EARS):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9779)
◆英語タイトル:Auris Medical Holding AG (EARS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9779
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:48
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Auris Medical Holding AG (Auris Medical) is a clinical-stage biopharmaceutical company with focus on neurotology and mental health supportive care. The company’s pipeline product candidates are in various clinical phases intended for the treatment of acute inner ear tinnitus, post-acute inner ear tinnitus, tinnitus, Meniere’s disease (Vertigo), sudden loss of hearing, antipsychotic-induced weight gain and somnolence. It has research collaboration and licensing agreements with research institutions such as King’s College London and pharmaceutical and biotechnology companies including Xigen and Inserm. Auris Medical is headquartered in Zug, Switzerland.

Auris Medical Holding AG (EARS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Auris Medical Acquires Intranasal Betahistine from Otifex Therapeutics 12
Venture Financing 13
Auris Medical Raises US$51 Million In Series C Financing 13
Partnerships 15
Auris Medical Extends its Drug Discovery Agreement with King’s College 15
Auris Medical Enters Into Agreement With Medidata Solutions 16
Equity Offering 17
Auris Medical Raises USD7 Million in Public Offering of Shares 17
Auris Medical to Raise Funds through Public Offering of shares 18
Auris Medical Raises USD5.5 Million in Public Offering of Shares 19
Auris Medical Raises USD10 Million in Public Offering of Units 20
Auris Medical to Raise up to USD35 Million in Public Offering of Shares 22
Auris Medical Raises USD25 Million in Public Offering of Shares 23
Auris Medical Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD60.7 Million 24
Auris Medical Holding AG – Key Competitors 26
Auris Medical Holding AG – Key Employees 27
Auris Medical Holding AG – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 15, 2018: Auris Medical announces second quarter 2018 financial results 29
May 15, 2018: Auris Medical Provides Business and Strategy Update and Reports First Quarter 2018 Financial Results 31
Mar 22, 2018: Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results 33
Nov 28, 2017: Auris Medical Reports Third Quarter 2017 Financial Results and Provides Business Update 35
Aug 10, 2017: Auris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results 37
May 11, 2017: Auris Medical Provides Business Update and Reports First Quarter 2017 Financial Results 39
Mar 14, 2017: Auris Medical Provides Business Update and Reports Full Year 2016 Financial Results 41
Corporate Communications 43
Sep 26, 2017: Auris Medical Provides Board of Directors Update 43
Product News 44
05/30/2018: Auris Medical to Host Key Opinion Leader Call Focused on AM-201 Program for Treating Major Side Effects of Antipsychotics on June 11, 2018 44
Mar 16, 2018: Auris’ tinnitus treatment fails late-stage study for the second time 45
02/03/2017: Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo 46
Clinical Trials 47
Feb 07, 2018: Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Auris Medical Acquires Intranasal Betahistine from Otifex Therapeutics 12
Auris Medical Raises US$51 Million In Series C Financing 13
Auris Medical Extends its Drug Discovery Agreement with King's College 15
Auris Medical Enters Into Agreement With Medidata Solutions 16
Auris Medical Raises USD7 Million in Public Offering of Shares 17
Auris Medical to Raise Funds through Public Offering of shares 18
Auris Medical Raises USD5.5 Million in Public Offering of Shares 19
Auris Medical Raises USD10 Million in Public Offering of Units 20
Auris Medical to Raise up to USD35 Million in Public Offering of Shares 22
Auris Medical Raises USD25 Million in Public Offering of Shares 23
Auris Medical Completes Underwriters Partial Exercise of Over-Allotment Option of IPO for USD60.7 Million 24
Auris Medical Holding AG, Key Competitors 26
Auris Medical Holding AG, Key Employees 27
Auris Medical Holding AG, Subsidiaries 28

List of Figures
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Auris Medical Holding AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Auris Medical Holding AG, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Auris Medical Holding AG (EARS):製薬・医療:M&Aディール及び事業提携情報(Auris Medical Holding AG (EARS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆